Edgestream Partners L.P. Acquires New Stake in Denali Therapeutics Inc. $DNLI

Edgestream Partners L.P. bought a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 342,923 shares of the company’s stock, valued at approximately $4,797,000. Edgestream Partners L.P. owned about 0.24% of Denali Therapeutics as of its most recent SEC filing.

A number of other large investors have also modified their holdings of DNLI. Schroder Investment Management Group lifted its stake in shares of Denali Therapeutics by 32.5% in the second quarter. Schroder Investment Management Group now owns 386,539 shares of the company’s stock worth $5,408,000 after buying an additional 94,744 shares in the last quarter. Norges Bank acquired a new stake in Denali Therapeutics in the 2nd quarter valued at about $55,224,000. Capital Fund Management S.A. acquired a new stake in Denali Therapeutics in the 2nd quarter valued at about $306,000. Groupama Asset Managment lifted its stake in Denali Therapeutics by 21.5% in the 2nd quarter. Groupama Asset Managment now owns 175,531 shares of the company’s stock worth $2,475,000 after purchasing an additional 31,043 shares in the last quarter. Finally, Ameritas Investment Partners Inc. boosted its holdings in shares of Denali Therapeutics by 7.4% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 13,522 shares of the company’s stock worth $189,000 after purchasing an additional 930 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Analyst Ratings Changes

DNLI has been the subject of several recent research reports. Morgan Stanley cut their price target on Denali Therapeutics from $33.00 to $30.00 and set an “overweight” rating for the company in a report on Monday, August 18th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Denali Therapeutics in a research note on Monday, September 8th. JPMorgan Chase & Co. boosted their price target on shares of Denali Therapeutics from $24.00 to $26.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Stifel Nicolaus set a $37.00 price objective on shares of Denali Therapeutics in a report on Monday, November 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $32.64.

Denali Therapeutics Trading Down 1.8%

NASDAQ DNLI opened at $17.84 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.79 and a quick ratio of 9.79. The stock has a market capitalization of $2.62 billion, a P/E ratio of -6.13 and a beta of 1.11. The firm’s 50-day moving average is $16.32 and its two-hundred day moving average is $15.02. Denali Therapeutics Inc. has a 12 month low of $10.57 and a 12 month high of $26.18.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.74) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.02. The company’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter last year, the business earned ($0.63) earnings per share. On average, sell-side analysts anticipate that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.